Rocky Mount Mending, But GMP ‘Issues’ Persist: Hospira CEO

Ongoing remediation at Hospira’s Rocky Mount, N.C., plant is on track with the aid of new hires and consultants, the company says. But lingering manufacturing issues there and a fresh FDA Form 483 and “untitled” letter could continue to drag the company’s sales. Plus some investors haven’t counted out the threat of a consent decree.
Drug Industry Daily